NSE · SOLARA
Solara Active Pharma Sciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹417 Cr with net profit ₹30 Cr — a 7.09% net margin, versus 4.45% the period before.
Shareholding
As of 2026-09-30
- Promoter41.93%
- Public46.48%
- FII10.71%
- DII0.88%
70,905 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #42 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Solara Active Pharma Sciences Ltd.(this company) | ₹3,075 Cr | 64.99 | 2.14 | 3.3% | 2.41% |
AI analysis
AI-generated · google/gemini-2.5-flashSolara Active Pharma Sciences Ltd. (SOLARA) is listed with a market capitalization of Rs 2728 Cr. The company reported a revenue of Rs 1292.08 Cr and an EPS of -0.27. As of May 31, 2026, promoter holding stands at 41.9965%, with 36.57% of promoter shares pledged.
Positives
- +The institutional holding is 15.1103% as of May 31, 2026.
- +The company's revenue for the fiscal year ending March 2025 was Rs 1292.08 Cr.
Negatives
- −The promoter holding has decreased from 48.58% pledged in Pronomz Ventures Llp to a total pledge of 36.57% of promoter shares.
- −The Return on Equity (ROE) is 0%, indicating no return on shareholders' equity.
- −The company reported a negative EPS of -0.27.
- −The Price-to-Earnings (PE) ratio is 0, consistent with the negative EPS.
- −The quarterly net profit fluctuates, with a net loss of Rs -17.43 Cr in Dec 2025.
Financial Performance
For the year ending March 2025, Solara Active Pharma Sciences Ltd. recorded a revenue of Rs 1292.08 Cr and a net profit of Rs 0.54 Cr, resulting in an EPS of Rs 0.14. Quarterly results for Dec 2025 show a revenue of Rs 349 Cr with a net loss of Rs -17.43 Cr. The most recent quarter, March 2026, generated a revenue of Rs 387.29 Cr and a net profit of Rs 9.6 Cr.
Profitability & Returns
The company reported a Return on Capital Employed (ROCE) of 4.8071%. The Return on Equity (ROE) is 0%, and the Price-to-Earnings (PE) ratio is 0, reflecting the negative EPS of -0.27. EBITDA for the year ending March 2025 was Rs 115.35 Cr.
Balance Sheet
Solara Active Pharma Sciences Ltd. has a book value of Rs 272.35. The debt-to-equity ratio is 0.89, indicating the company's reliance on debt financing. The company's highest 52-week share price was Rs 734.4, while the lowest was Rs 422.
Ownership & Pledges
A significant portion of promoter shares, 36.57%, is pledged. Total institutional holding is 15.1103%.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Solara Active Pharma Sciences Ltd.share price & fundamentals